Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Chronic hyperglycemia impairs insulin action, resulting in glucotoxicity, which can be ameliorated in animal models by inducing glucosuria with renal glucose transport inhibitors. Here, we examined whether reduction of plasma glucose with a sodium-glucose cotransporter 2 (SGLT2) inhibitor could improve insulin-mediated tissue glucose disposal in patients with type 2 diabetes. Eighteen diabetic men were randomized to receive either dapagliflozin (n = 12) or placebo (n = 6) for 2 weeks. We measured insulin-mediated whole body glucose uptake and endogenous glucose production (EGP) at baseline and 2 weeks after treatment using the euglycemic hyperinsulinemic clamp technique. Dapagliflozin treatment induced glucosuria and markedly lowered fasting plasma glucose. Insulin-mediated tissue glucose disposal increased by approximately 18% after 2 weeks of dapagliflozin treatment, while placebo-treated subjects had no change in insulin sensitivity. Surprisingly, following dapagliflozin treatment, EGP increased substantially and was accompanied by an increase in fasting plasma glucagon concentration. Together, our data indicate that reduction of plasma glucose with an agent that works specifically on the kidney to induce glucosuria improves muscle insulin sensitivity. However, glucosuria induction following SGLT2 inhibition is associated with a paradoxical increase in EGP. These results provide support for the glucotoxicity hypothesis, which suggests that chronic hyperglycemia impairs insulin action in individuals with type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Long-term effects of sodium-glucose transport protein 2 inhibitors (SGLT2i) might enhance insulin sensitivity, thereby mitigating muscle catabolism and influencing the quality and functionality of the skeletal muscle.30,31”
From Imaging of Sarcopenia in Type 2 Diabetes Mellitus (2024) · cites this paper as [31]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glucose clamp technique: a method for quantifying insulin secretion and resistance.
DeFronzo, R. A., Tobin, J. D., & Andres, R. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.237.3.e214 · Cited by 7,425 · cited 2×
“After the start of insulin, no glucose was infused until the plasma glucose concentration declined to 100 mg/dl, at which level it was maintained by the adjustment of a variable glucose infusion based on the negative feedback principle (27).”
Self-citationDeFronzo, R. A., Jacot, E., Jequier, E., Maeder, E., Wahren, J., & Felber, J. P. (1981) · Diabetes · doi:10.2337/diab.30.12.1000 · Cited by 1,770 · cited 1×
“Since >80% of insulin-mediated glucose disposal during the euglycemic insulin clamp takes place in skeletal muscle (16), these results indicate that lowering the plasma glucose concentration in T2DM significantly improves muscle insulin resistance and are consistent with a glucotoxic effect of chronic hyperglycemia to…”
Self-citationMeasurement of Size and Turnover Rate of Body Glucose Pool by the Isotope Dilution Method
Steele, R., Wall, J. S., de Bodo, R. C., & Altszuler, N. (1956) · American Journal of Physiology-Legacy Content · doi:10.1152/ajplegacy.1956.187.1.15 · Cited by 816 · cited 1×
“After drug administration and during the insulin clamp, nonsteady-state conditions for 3-3 H-glucose–specific activity prevail and the rate of glucose appearance ( R a ) was calculated with Steele’s equation (28).”
Groop, L. C., Bonadonna, R. C., DelPrato, S., Ratheiser, K., Zyck, K., Ferrannini, E., & DeFronzo, R. A. (1989) · Journal of Clinical Investigation · doi:10.1172/jci114142 · Cited by 812 · cited 1×
“However, these latter studies are difficult to interpret, since insulin therapy also exerts other metabolic effects, e.g., reduction in plasma free fatty acid concentration (12), which profoundly affect insulin sensitivity independent of changes in plasma glucose concentration (13).”
Self-citationRossetti, L., Smith, D., Shulman, G. I., Papachristou, D., & DeFronzo, R. A. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112981 · Cited by 809
Self-citationRossetti, L., Giaccari, A., & DeFronzo, R. A. (1990) · Diabetes Care · doi:10.2337/diacare.13.6.610 · Cited by 770
Self-citationDeFronzo, R. A., Ferrannini, E., & Simonson, D. C. (1989) · Metabolism · doi:10.1016/0026-0495(89)90129-7 · Cited by 515 · cited 1×
“Because of the close relationship between EGP (primarily reflects liver) and the fasting plasma glucose concentration (17), the decrease in FPG brought about by dapagliflozin would be expected to be associated with a decrease in HGP.”
Self-citationBanting Lecture 1997. Control of glucose uptake and release by the liver in vivo.
Cherrington, A. D. (1999) · Diabetes · doi:10.2337/diabetes.48.5.1198 · Cited by 502
Role of Sodium-Glucose Cotransporter 2 (SGLT 2) Inhibitors in the Treatment of Type 2 Diabetes
Abdul-Ghani, M. A., Norton, L., & DeFronzo, R. A. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0029 · Cited by 443 · cited 1×
“…the impact of chronic hyperglycemia on insulin sensitivity in individuals with T2DM, we examined the effect of lowering the plasma glucose concentration on whole body insulin sensitivity by inhibiting renal sodium-glucose cotransport with dapagliflozin (15) using the insulin clamp technique.”
Self-citationDose-Response Effect of Elevated Plasma Free Fatty Acid on Insulin Signaling
Belfort, R., Mandarino, L., Kashyap, S., Wirfel, K., Pratipanawatr, T., Berria, R., DeFronzo, R. A., & Cusi, K. (2005) · Diabetes · doi:10.2337/diabetes.54.6.1640 · Cited by 404 · cited 1×
“However, these latter studies are difficult to interpret, since insulin therapy also exerts other metabolic effects, e.g., reduction in plasma free fatty acid concentration (12), which profoundly affect insulin sensitivity independent of changes in plasma glucose concentration (13).”
Self-citationDel Prato, S., Leonetti, F., Simonson, D. C., Sheehan, P., Matsuda, M., & DeFronzo, R. A. (1994) · Diabetologia · doi:10.1007/bf00400466 · Cited by 322 · cited 3×
“In individuals with normal glucose tolerance (NGT), a modest elevation in day-long plasma glucose concentration for 24 hours causes a 29% decrease in whole body insulin-mediated glucose disposal (7), and similar observations have been made in individuals with type 1 diabetes (8).”
Self-citationZambrowicz, B., Freiman, J., Brown, P. M., Frazier, K. S., Turnage, A., Bronner, J., Ruff, D., Shadoan, M., Banks, P., Mseeh, F., et al. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.58 · Cited by 243 · cited 1×
“Of note, clinical trials with other SGLT2 inhibitors have reported an increase in plasma glucagon concentration despite a decrease in FPG concentration (21).”
Insulin Treatment Reverses the Insulin Resistance of Type II Diabetes Mellitus
Scarlett, J. A., Gray, R. S., Griffin, J., Olefsky, J. M., & Kolterman, O. G. (1982) · Diabetes Care · doi:10.2337/diacare.5.4.353 · Cited by 216 · cited 1×
“Conversely, lowering the plasma glucose concentration with insulin therapy in individuals with T2DM significantly improves insulin-mediated glucose disposal (10, 11).”
Microvascular complications of diabetes
He, Z., & King, G. L. (2004) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2003.12.003 · Cited by 169 · cited 1×
“Introduction Hyperglycemia is a sine qua non in type 2 diabetes mellitus (T2DM), and it is the principle factor responsible for the development of diabetic microvascular complications (1).”
BackgroundRegulation of hepatic glucose metabolism in humans
DeFronzo, R. A., & Ferrannini, E. (1987) · Diabetes/Metabolism Reviews · doi:10.1002/dmr.5610030204 · Cited by 167 · cited 6×
“Note the break in the time scale ( x axis) between days 2 and 3 and between days 3 and 14. glucagon concentration, in the face of a decrease in plasma insulin concentration, led to a marked increase in the plasma glucagon/ insulin ratio, which is an important regulator of HGP (19).”
BackgroundInfluentialSelf-citationZierath, J. R., Galuska, D., Nolte, L. A., Th�rne, A., Kristensen, J. S., & Wallberg‐Henriksson, H. (1994) · Diabetologia · doi:10.1007/bf00398054 · Cited by 113 · cited 1×
“Studies in experimental animals (2–6) using the insulin clamp technique have demonstrated that even small persistent increases in the plasma glucose concentration impair insulin-mediated glucose disposal.”
Vuorinen-Markkola, H., Koivisto, V. A., & Yki-Jarvinen, H. (1992) · Diabetes · doi:10.2337/diab.41.5.571 · Cited by 109
Insulin regulation of renal glucose metabolism in humans
Cersosimo, E., Garlick, P., & Ferretti, J. (1999) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1999.276.1.e78 · Cited by 97 · cited 1×
“It has been estimated that as much as 15% to 20% of basal EGP comes from the kidney (22, 23).”
Matsuda, M., DeFronzo, R. A., Glass, L. C., Consoli, A., Giordano, M., Bressler, P., & DelPrato, S. (2002) · Metabolism · doi:10.1053/meta.2002.34700 · Cited by 85
Self-citationDeFronzo, R. A., Andres, R., Bledsoe, T. A., Boden, G., Faloona, G. A., & Tobin, J. D. (1977) · Diabetes · doi:10.2337/diab.26.5.445 · Cited by 70
Self-citationBurén, J., Lindmark, S., Renström, F., & Eriksson, J. W. (2003) · Metabolism · doi:10.1053/meta.2003.50041 · Cited by 55 · cited 1×
“Moreover, correction of the hyperglycemia restores normal tissue responsiveness to insulin (3, 5).”
Current strategies for the inhibition of hepatic glucose production in type 2 diabetes
Edgerton, D. (2009) · Frontiers in Bioscience · doi:10.2741/3301 · Cited by 54 · cited 1×
“It would be of great interest to examine combination therapy with SGLT2 inhibitor plus an incretin mimetic agent that inhibits glucagon and stimulates insulin secretion (26).”
Solomon, T. P. J., Knudsen, S. H., Karstoft, K., Winding, K., Holst, J. J., & Pedersen, B. K. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2097 · Cited by 51 · cited 1×
“In individuals with normal glucose tolerance (NGT), a modest elevation in day-long plasma glucose concentration for 24 hours causes a 29% decrease in whole body insulin-mediated glucose disposal (7), and similar observations have been made in individuals with type 1 diabetes (8).”
Lindmark, S., Burén, J., & Eriksson, J. W. (2006) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02593.x · Cited by 46
Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
Merovci, A., Solis‐Herrera, C., Daniele, G., Eldor, R., Fiorentino, T. V., Tripathy, D., Xiong, J., Perez, Z., Norton, L., Abdul‐Ghani, M. A., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci76184 · Cited by 27
Self-citationEffects of hyperglycemia, glucagon, and epinephrine on renal glucose release in the conscious dog
Gustavson, S. M., Chu, C. A., Nishizawa, M., Neal, D. W., Farmer, B., Yang, Y., Donahue, E. P., Flakoll, P. J., & Cherrington, A. D. (2004) · Metabolism · doi:10.1016/j.metabol.2004.01.018 · Cited by 25 · cited 1×
“However, the kidney does not respond to glucagon with an increase in glucose output (24).”
Role of the kidney in hyperglycemia in type 2 diabetes
Meyer, C., & Gerich, J. E. (2002) · Current Diabetes Reports · doi:10.1007/s11892-002-0089-z · Cited by 18 · cited 1×
“It has been estimated that as much as 15% to 20% of basal EGP comes from the kidney (22, 23).”
BackgroundInfluence of insulin treatment on insulin sensitivity in insulin requiring type 2 diabetes patients
Mayorov, A. Y., Naumenkova, I., Antsiferov, M. B., & Dedov, I. I. (2005) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2005.03.007 · Cited by 11 · cited 1×
“Conversely, lowering the plasma glucose concentration with insulin therapy in individuals with T2DM significantly improves insulin-mediated glucose disposal (10, 11).”
Research works printed but not linked: 1
- Del Prato S, Leonetti F, Simonson DC, Sheehan P, Matsuda M, DeFronzo RA. Effect of sustained physiologic hyperinsulinaemia and hyperglycaemia on insulin secretion and insulin sensitivity in man. Diabetologia. 1994;37(10):1025-1035. · DOI · Paper page
Cited by
DeFronzo, R. A., Ferrannini, E., Groop, L., Henry, R. R., Herman, W. H., Holst, J. J., Hu, F. B., Kahn, C. R., Raz, I., Shulman, G. I., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.19 · Cited by 2,611
Self-citationPeters, A. L., Buschur, E. O., Buse, J. B., Cohan, P., Diner, J. C., & Hirsch, I. B. (2015) · Diabetes Care · doi:10.2337/dc15-0843 · Cited by 849
“Furthermore, SGLT-2 inhibitors are associatedwith an increase in plasma glucagon levels throughuncertainmechanisms (19,20).”
BackgroundBonner, C., Kerr-Conte, J., Gmyr, V., Queniat, G., Moerman, E., Thévenet, J., Beaucamps, C., Delalleau, N., Popescu, I., Malaisse, W. J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3828 · Cited by 670
Rosenstock, J., & Ferrannini, E. (2015) · Diabetes Care · doi:10.2337/dc15-1380 · Cited by 664
“of the euglycemic insulin clamp, as a result of attenuated glucotoxicity (21).”
BackgroundVallon, V., & Thomson, S. C. (2017) · Diabetologia · doi:10.1007/s00125-016-4157-3 · Cited by 635
“As indicated by preclinical [34–36] and clinical studies [32, 37], this also applies to SGLT2 inhibition.”
Background
Metadata
- Authors
- Merovci, A., Solis-Herrera, C., Daniele, G., Eldor, R., Fiorentino, T. V., Tripathy, D., Xiong, J., Perez, Z., Norton, L., Abdul-Ghani, M. A., & DeFronzo, R. A.
- Affiliations
- The University of Texas at San Antonio Health Science Center (US)
- Corresponding author
- DeFronzo, Ralph A.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2014-01-27
- Volume
- 124
- Issue
- 2
- Pages
- 509-514
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3904617
- OpenAlex
- W2166613497
- Cited by
- 795
- References
- 28
- Citations by year
- 2026: 26 · 2025: 40 · 2024: 52 · 2023: 55 · 2022: 64 · 2021: 58 · 2020: 91 · 2019: 63 · 2018: 71 · 2017: 71 · 2016: 79 · 2015: 82 · 2014: 43
- FWCI
- 73.77
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Funders
- Bristol-Myers Squibb
- National Institutes of Health (UL1TR001120, 5R01DK240923, KL2TR001118)
- University of Texas Health Science Center at San Antonio
- National Institute of Diabetes and Digestive and Kidney Diseases (5R01DK240923, R01DK024092)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- dapagliflozin, SGLT2 inhibitors, type 2 diabetes, skeletal muscle insulin sensitivity, endogenous glucose production, glycosuria, glucotoxicity, hyperglycemia, insulin-stimulated glucose disposal, glucagon, renal glucose transport
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Benzhydryl Compounds, Blood Glucose, Body Weight, Diabetes Mellitus, Type 2, Fasting, Glucagon, Glucose, Glucosides, Humans, Hyperglycemia, Insulin, Male, Metformin, Middle Aged, Muscles, Sulfonylurea Compounds, Time Factors, Glucose Clamp Technique, Sodium-Glucose Transporter 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.